Enßle, Julius C.
Wolf, Sebastian
Scheich, Sebastian
Weber, Sarah
Kramer, Michael
Ruhnke, Leo
Schliemann, Christoph http://orcid.org/0000-0003-1755-9583
Mikesch, Jan-Henrik
Krause, Stefan http://orcid.org/0000-0002-5259-4651
Sauer, Tim
Hanoun, Maher http://orcid.org/0000-0002-1754-8940
Reinhardt, Hans Christian
Kraus, Sabrina
Kaufmann, Martin
Hänel, Mathias
Fransecky, Lars
Burchert, Andreas http://orcid.org/0000-0002-8411-8844
Neubauer, Andreas http://orcid.org/0000-0002-7606-8760
Crysandt, Martina
Jost, Edgar
Niemann, Dirk
Schäfer-Eckart, Kerstin
Held, Gerhard
Kaiser, Ulrich
Wass, Maxi
Schaich, Markus
Müller-Tidow, Carsten http://orcid.org/0000-0002-7166-5232
Platzbecker, Uwe
Baldus, Claudia D.
Bornhäuser, Martin
Röllig, Christoph http://orcid.org/0000-0002-3791-0548
Serve, Hubert http://orcid.org/0000-0001-8472-5516
Steffen, Björn http://orcid.org/0009-0002-6693-4079
,
Article History
Received: 5 January 2023
Revised: 6 June 2023
Accepted: 5 July 2023
First Online: 4 August 2023
Competing interests
: CS received honoraria from AbbVie, Astellas, AstraZeneca, BMS/Celgene, Jazz Pharmaceuticals, Novartis, Pfizer and Roche. B.S. received travel support from Pfizer, Jazz Pharmaceuticals and AbbVie. The remaining authors declare no competing interests.
: As a non-interventional study documenting disease and treatment characteristics as well as outcome data, all ethics committees of the 46 participating centres in Germany approved the study protocol of the SAL-AML registry with local ethics approval and the study is registered on clinicaltrials.gov (NCT03188874). All patients declared informed consent.
: Not applicable.